ONCOLOGY LYOPHILIZED INJECTABLES

At VENUS REMEDIES LIMITED, we approach business partnerships with a strategic mindset, fostering collaboration that is not only successful in the short term but also sustainable and mutually beneficial in the long run.

CEFEPIME FOR INJECTION | CEFTRIAXONE | CEFTAZIDIME FOR INJECTION | CEFOPERAZONE + SULBACTAM FOR INJECTION | CEFUROXIME FOR INJECTION | CEFOTAXIME FOR INJECTION | CEFTAZIDIME AVIBACTAM FOR INJECTION | CEFTRIAXONE SULBACTAM FOR INJECTION | ELORES: CEFTRIAXONE, SULBACTAM & EDTA FOR INJECTION | AZTREONAM F...

CARBOPLATIN | CISPLATIN | CYTARABINE LIQUID | DOCETAXEL WITH SOLVENT | DOCETAXEL (CTD) SINGLE VIAL | DOXORUBICIN | EPIRUBICINE | ETOPOSIDE  | IRINOTECAN | LEUCOVORIN CALCIUM | METHOTREXATE | OXALIPLATIN | PLERIXAFOR | PACLITAXEL  | VINCRISTINE | 5-FLOUROURACIL | FULVESTRANT

ENOXAPARIN PFS 100MG/ML

Venus Pharma GmbH became the first company to introduce Meropenem 2000 mg. Also received Meropenem Prequalification from WHO.

REMDESIVIR FOR INJECTION | ACECLOFENAC | CISATRACURIUM BESYLATE | CITICOLINE | DEXMETOMIDINE | L-ORNITHINE L-ASPARTATE | MIDAZOLAM INJ | N-ACETYLCYSTEINE | SUGAMMADEX| PARACETAMOL.

Pharma major Venus Remedies Limited has recently made significant progress in its global expansion by obtaining marketing approvals (MAs) for a wide range of drugs in different countries. We’re excited to share that Carboplatin and Carbol have been approved in Morocco, along with Bortezomib, Gemcitabine, Cefepime, and Oxaliplatin in the Philippines. In addition, we have received approvals for Meropenem in Hong Kong, Ceftriaxone in Mauritania, Methotrexate in Saudi Arabia, Imipenem/Cilastatin in Slovenia, Docetaxel in Portugal, and Ronem in El Salvador.

Venus Remedies and West Pharmaceutical Packaging @westatwork Kriti Kotian, Marketing Specialist at West Pharmaceutical Packaging India.

Venus Remedies is thrilled to announce a major achievement: our pre-filled syringe (PFS) manufacturing unit in Baddi has been awarded the prestigious PIC/S GMP certification by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). This is the first time our PFS facility has received accreditation under the Pharmaceutical Inspection Co-operation Scheme (PIC/S), marking an important step in our journey to bring world-class healthcare solutions to new markets.

Join Venus Remedies and Venus Pharma GmbH at CPhI Milan 2024, from October 8th to 10th, in Hall 14, Meeting Rooms G52 & G54.

Venus Remedies is thrilled to announce a significant achievement in its ongoing mission to enhance cancer care with innovative solutions. The company's German subsidiary, Venus Pharma GmbH, has secured market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion, marking a remarkable milestone for the organization.

Venus Remedies Global Presence -96+ countries

Venus Remedies: A Global Pharma Force with Presence in 100 Countries and 800+ Marketing Authorizations

Venus Pharma GmbH is committed to the fight against cancer through itsadvanced range of Anticancer Injectables. Our products are designed to provide effective treatment options that address the unique needsof cancer patients. With a focus on precision, safety, and innovation, our injectables are developed using state-of-the-art technologies and rigorous quality standards. We aim to enhance patient outcomes and improve quality of life through therapies that target cancer at its core while minimizing adverse effects.

What an incredible final day at CPhI 2024! Venus Remedies wrapped up this amazing event with innovative showcases and powerful conversations with industry leaders. Thank you to everyone who joined us on this journey! Swipe to catch day 3 highlights!

Our efforts are well recognitioned by global regulatory authorities.Venus's passion for quality is reflected in its ability to align its organization-wide operations to global standards enabling it to secure global and national endorsements – its manufacturing facilities have thus far obtained more than 20 gmp approvals.

Venus Meropenem is revolutionizing the fight against serious bacterial infections. With its broad-spectrum action, it effectively targets conditions like pneumonia and urinary tract infections, providing healthcare professionals with a reliable solution. This innovative antibiotic exemplifies the advancements in medical treatment, ensuring better outcomes for patients facing complex infections.

Venus Remedies Limited is delighted to announce the successful registration of our Unit-2 in Baddi and Venus Pharma GmbH from Kuwait, alongside obtaining Marketing Authorizations (MAs) for Carboplatin 450 MG/45 ML. These achievements mark significant milestones in our ongoing commitment to expanding our global footprint and enhancing our pharmaceutical capabilities.

Venus' Product List for CPHI 2025